Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.

There is gain in loss.

wallstreetcn21:26 ET

WUXI APPTEC will transfer the WuXi ATU Business to a USA Fund. Is the "optimal solution" for the "gray rhino" of the Biological Safety Act?

① This evening, WUXI APPTEC announced that it will transfer its WuXi ATU Business in the USA and United Kingdom to the USA Private Equity Fund Altaris in exchange for Cash.; ② In the first three quarters, WuXi ATU achieved revenue of 0.853 billion, accounting for only about 3% of the total revenue for the first three quarters.; ③ After the transfer of this Business, the accusations and suspicions related to its gene business may be cleared under the Biosecurity Act.

cls.cnDec 24 10:58 ET

WuXi AppTec Sells Therapy Units to Altaris LLC

TipRanksDec 24 09:08 ET

Express News | WuXi AppTec - Units to Sell All of Shares in Wuxi Advanced Therapies Inc. to Altaris LLC

ReutersDec 24 08:37 ET

Express News | WuXi AppTec - Business Update in Connection With Wuxi Atu Business

ReutersDec 24 08:37 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 04:16 ET